Novo Nordisk infuses DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark
Denmark: Novo Nordisk has announced plans to invest 15.9 billion Danish kroner starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.
The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where 21,000-plus employees – approximately half of the company's global workforce - still work today. The majority of these employees work at various production sites.
The new facility – which will be approximately 65,000m² – will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment.
Construction is underway and the facility is expected to start producing API by early 2029. This project is expected to create 340 new jobs when construction is completed, and the facility is fully equipped.
Read also: Novo Nordisk enters exclusive negotiations to acquire controlling stake in BIOCOR
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.